Article
Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Oct 2016
Alegre E, Fusco J P, Restituto P, Salas-Benito D, Rodríguez-Ruiz M E, Andueza M P, Pajares M J, Patiño-García A, Pio R, Lozano M D, Gúrpide A, Lopez-Picazo J M, Gil-Bazo I, Perez-Gracia J L, Gonzalez A
Abstract excerpt
Mutation analysis of epidermal growth factor receptor (EGFR) gene is essential for treatment selection in non-small cell lung cancer (NSCLC). Analysis is usually performed in tumor samples. We evaluated the clinical utility of EGFR analysis in plasma cell-free DNA (cfDNA) from patients under treatment with EGFR inhibitors. We selected 36 patients with NSCLC and EGFR-activating mutations. Blood samples were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.